Pfizer signs strategic cooperation pact with Sinopharm
Advertisement
United States: Pfizer said on Thursday it has signed a strategic cooperation agreement with China's Sinopharm Group, and plans to seek approval to market 12 innovative drugs in China through 2025.
Read also: USFDA accepts Pfizer supplemental new drug applications for BRAFTOVI plus MEKTOVI
Sinopharm's president Liu Yong said during the signing event in Shanghai on Wednesday that the cooperation will involve accelerating the delivery of Pfizer's new drugs to patients, according to a statement from Pfizer.
Read also: Pfizer RSV vaccine 82 percent effective in severe infection in infants: Data
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.